Identification of Genes and Cellular Response Factors Related to Immunotherapy Response in Mismatch Repair-proficient Colorectal Cancer: a Bioinformatics Analysis

Overview

Journal J Gastrointest Oncol

Date 2023 Jan 13

PMID 36636048

Authors

Wenxiu Xue

Jinglong Shi

Affiliations

Soon will be listed here.

Abstract

Background: Mismatch repair-proficient (pMMR) colorectal cancers (CRCs) are thought to be primarily resistant to immune checkpoint inhibitor (ICI) monotherapy. However, recent clinical trials have reported that early-to-mid stage (non-metastatic) CRC responds well to ICI monotherapy. We hypothesized that the efficacy of immunotherapy is linked to a series of gene expression profiles that can characterize the pMMR CRC disease stage.

Methods: Using The Cancer Genome Atlas (TCGA) CRC data sets, we first investigated transcriptomic features that continuously changed (were continuously upregulated or downregulated) with pMMR CRC disease-stage progression. We defined these gene sets as stage-associated genes. The deconvolution algorithm then enriched these genes with the dynamic changes in the cell type populations of the CRC tumor microenvironment (TME). Finally, the stage-associated genes were cross-referenced to the current transcriptome profile data on ICI treatment of pMMR CRC, which revealed the gene set specifying an effective pMMR tumor response.

Results: In total, 774 genes were found to increase in expression and 845 genes to decrease in expression as the stage increased. Using deconvolution methods, we discovered 2 major disease stage-associated alterations in the cellular composition of pMMR CRCs, including changes in cell types involved in host immune responses and tumor cell metastasis. The central memory CD8 T cell population decreased as the pMMR CRC disease stage increased, but the endothelial cell populations associated with proliferation and metastasis increased. Using a different cell type annotation set (LM22), we discovered that as the disease progressed, M1 macrophages and CD8 T cells decreased in the TME. In mismatch repair-deficient patients with CRC, however, such a decrease was not observed. Finally, we identified 27 signature genes that can be used to assess ICI efficacy in treatment-naïve patients with pMMR CRC.

Conclusions: The current study sought to identify the underlying molecular mechanisms, pathways, and cell landscapes that explain why early-to-mid stage pMMR CRC responds well to ICI treatment. This analysis might be valuable for the selection of patients who might benefit from immunotherapeutic strategies.

Citing Articles

Community assessment of methods to deconvolve cellular composition from bulk gene expression.

White B, De Reynies A, Newman A, Waterfall J, Lamb A, Petitprez F Nat Commun. 2024; 15(1):7362.

PMID: 39191725 PMC: 11350143. DOI: 10.1038/s41467-024-50618-0.

References

Newman A, Steen C, Liu C, Gentles A, Chaudhuri A, Scherer F . Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019; 37(7):773-782. PMC: 6610714. DOI: 10.1038/s41587-019-0114-2. View

Dunn G, Bruce A, Ikeda H, Old L, Schreiber R . Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3(11):991-8. DOI: 10.1038/ni1102-991. View

Love M, Huber W, Anders S . Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15(12):550. PMC: 4302049. DOI: 10.1186/s13059-014-0550-8. View

Molodtsov A, Turk M . Tissue Resident CD8 Memory T Cell Responses in Cancer and Autoimmunity. Front Immunol. 2018; 9:2810. PMC: 6281983. DOI: 10.3389/fimmu.2018.02810. View

Salem A, Alotaibi M, Mroueh R, Basheer H, Afarinkia K . CCR7 as a therapeutic target in Cancer. Biochim Biophys Acta Rev Cancer. 2021; 1875(1):188499. DOI: 10.1016/j.bbcan.2020.188499. View

Chalabi M, Fanchi L, Dijkstra K, van den Berg J, Aalbers A, Sikorska K . Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 2020; 26(4):566-576. DOI: 10.1038/s41591-020-0805-8. View

Cook M, Hurwitz L, Geczik A, Butler E . An Up-to-date Assessment of US Prostate Cancer Incidence Rates by Stage and Race: A Novel Approach Combining Multiple Imputation with Age and Delay Adjustment. Eur Urol. 2020; 79(1):33-41. PMC: 8853735. DOI: 10.1016/j.eururo.2020.09.041. View

Huang A, Orlowski R, Xu X, Mick R, George S, Yan P . A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat Med. 2019; 25(3):454-461. PMC: 6699626. DOI: 10.1038/s41591-019-0357-y. View

Klement J, Paschall A, Redd P, Ibrahim M, Lu C, Yang D . An osteopontin/CD44 immune checkpoint controls CD8+ T cell activation and tumor immune evasion. J Clin Invest. 2018; 128(12):5549-5560. PMC: 6264631. DOI: 10.1172/JCI123360. View

10.

Hu X, Li Y, Li Q, Ma Y, Peng J, Cai S . ITGAE Defines CD8+ Tumor-Infiltrating Lymphocytes Predicting a better Prognostic Survival in Colorectal Cancer. EBioMedicine. 2018; 35:178-188. PMC: 6154785. DOI: 10.1016/j.ebiom.2018.08.003. View

11.

Schreiber R, Old L, Smyth M . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. DOI: 10.1126/science.1203486. View

12.

Han J, Khatwani N, Searles T, Turk M, Angeles C . Memory CD8 T cell responses to cancer. Semin Immunol. 2020; 49:101435. PMC: 7738415. DOI: 10.1016/j.smim.2020.101435. View

13.

Andre T, Shiu K, Kim T, Jensen B, Jensen L, Punt C . Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med. 2020; 383(23):2207-2218. DOI: 10.1056/NEJMoa2017699. View

14.

Gong J, Wang C, Lee P, Chu P, Fakih M . Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a Mutation. J Natl Compr Canc Netw. 2017; 15(2):142-147. DOI: 10.6004/jnccn.2017.0016. View

15.

Tcyganov E, Mastio J, Chen E, Gabrilovich D . Plasticity of myeloid-derived suppressor cells in cancer. Curr Opin Immunol. 2018; 51:76-82. PMC: 5943174. DOI: 10.1016/j.coi.2018.03.009. View

16.

Schadendorf D, Hodi F, Robert C, Weber J, Margolin K, Hamid O . Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol. 2015; 33(17):1889-94. PMC: 5089162. DOI: 10.1200/JCO.2014.56.2736. View

17.

Le D, Uram J, Wang H, Bartlett B, Kemberling H, Eyring A . PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015; 372(26):2509-20. PMC: 4481136. DOI: 10.1056/NEJMoa1500596. View

18.

Ling B, Watt K, Banerjee S, Newsted D, Truesdell P, Adams J . A novel immunotherapy targeting MMP-14 limits hypoxia, immune suppression and metastasis in triple-negative breast cancer models. Oncotarget. 2017; 8(35):58372-58385. PMC: 5601659. DOI: 10.18632/oncotarget.17702. View

19.

Forde P, Chaft J, Smith K, Anagnostou V, Cottrell T, Hellmann M . Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med. 2018; 378(21):1976-1986. PMC: 6223617. DOI: 10.1056/NEJMoa1716078. View

20.

Yang X, Lin Y, Shi Y, Li B, Liu W, Yin W . FAP Promotes Immunosuppression by Cancer-Associated Fibroblasts in the Tumor Microenvironment via STAT3-CCL2 Signaling. Cancer Res. 2016; 76(14):4124-35. DOI: 10.1158/0008-5472.CAN-15-2973. View